View Filing Data

Document and Entity Information - shares	6 Months Ended
Jun. 30, 2017	Aug. 03, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		59,459,438

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 104,872	$ 107,959
Restricted cash	1,831	1,831
Short-term investments	55,354	11,160
Accounts receivable, net of allowance for doubtful accounts of $637 and $484	26,731	19,827
Inventories	14,548	11,799
Prepaid expenses	1,336	1,722
Other current assets	1,027	2,143
Total current assets	205,699	156,441
PROPERTY AND EQUIPMENT, net	20,291	20,033
INTANGIBLE ASSETS, net	9,343	10,337
GOODWILL	19,482	18,793
OTHER ASSETS	3,536	2,331
TOTAL ASSETS	258,351	207,935
CURRENT LIABILITIES:
Accounts payable	9,623	4,633
Deferred revenue	1,477	1,388
Accrued expenses	12,092	11,314
Total current liabilities	23,192	17,335
OTHER LIABILITIES	3,538	2,304
DEFERRED INCOME TAXES	2,209	2,446
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 59,330 and 56,001 shares issued and outstanding	0	0
Additional paid-in capital	373,964	350,528
Accumulated other comprehensive loss	(11,963)	(14,220)
Accumulated deficit	(132,589)	(150,458)
Total stockholders' equity	229,412	185,850
Total liabilities and stockholders' equity	$ 258,351	$ 207,935

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
NET REVENUES:
Product	$ 39,132	$ 27,582	$ 70,614	$ 52,827
Other	1,044	3,777	2,108	7,621
Total revenue	40,176	31,359	72,722	60,448
COST OF PRODUCTS SOLD	14,699	10,274	26,935	19,050
Gross profit	25,477	21,085	45,787	41,398
OPERATING EXPENSES:
Research and development	3,338	2,985	6,308	5,351
Sales and marketing	7,502	7,397	14,379	16,103
General and administrative	7,750	6,354	14,842	12,896
Gain on litigation settlement			(12,500)
Total operating expenses	18,590	16,736	23,029	34,350
Operating income	6,887	4,349	22,758	7,048
OTHER INCOME (EXPENSE)	96	(340)	563	(532)
Income before income taxes	6,983	4,009	23,321	6,516
INCOME TAX EXPENSE	1,555	173	5,452	234
NET INCOME	$ 5,428	$ 3,836	$ 17,869	$ 6,282
EARNINGS PER SHARE:
BASIC	$ 0.09	$ 0.07	$ 0.31	$ 0.11
DILUTED	$ 0.09	$ 0.07	$ 0.30	$ 0.11
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	58,478	55,543	57,708	55,497
DILUTED	60,728	56,208	59,755	56,144

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
OPERATING ACTIVITIES:
Net income	$ 17,869	$ 6,282
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	3,631	2,942
Depreciation and amortization	2,891	2,738
Unrealized foreign currency loss	178	115
Deferred income taxes	(322)	(44)
Changes in assets and liabilities
Accounts receivable	(6,923)	893
Inventories	(2,680)	1,949
Prepaid expenses and other assets	1,525	17
Accounts payable	4,739	(782)
Deferred revenue	83	4,083
Accrued expenses and other liabilities	713	(1,452)
Net cash provided by operating activities	21,704	16,741
INVESTING ACTIVITIES:
Purchases of short-term investments	(62,233)	(15,335)
Proceeds from maturities and redemptions of short-term investments	18,585	15,335
Purchases of property and equipment	(1,567)	(2,729)
Net cash used in investing activities	(45,215)	(2,729)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	21,014	209
Repurchase of common stock	(1,209)	(3,311)
Net cash provided by (used in) financing activities	19,805	(3,102)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	619	697
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(3,087)	11,607
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	109,790	94,094
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	106,703	105,701
Cash paid for income taxes	4,325	556
Noncash investing activities (accrued property and equipment purchases)	$ 412	$ 287

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments. We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities at June 30, 2017 and December 31, 2016:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2017
Guaranteed investment certificates	$	19,281	$	—	$	—		$	19,281
Corporate bonds		36,128		—		(55	)		36,073

Total available-for-sale securities	$	55,409	$	—	$	(55	)	$	55,354

December 31, 2016
Guaranteed investment certificates	$	11,160	$	—	$	—		$	11,160

Total available-for-sale securities	$	11,160	$	—	$	—		$	11,160

At June 30, 2017 maturities of our available-for-sale securities were as follows:
Less than one year	$	55,409	$	—	$	(55	)	$	55,354

Fair Value of Financial Instruments. As of June 30, 2017 and December 31, 2016, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2017 and December 31, 2016.

Included in cash and cash equivalents at June 30, 2017 and December 31, 2016, was $60,987 and $83,704 invested in government money market funds. These funds hold investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of June 30, 2017 and December 31, 2016 was $3,220 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.

In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.68% to 0.84% and mature monthly through February 28, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 7 – Commitments and Contingencies.

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2017		December 31, 2016
Raw materials	$	5,410	$	5,399
Work in process		1,305		1,034
Finished goods		7,833		5,366

	$	14,548	$	11,799

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of June 30, 2017 and December 31, 2016 was $37,709 and $36,067, respectively.

Intangible Assets. Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Accumulated amortization of intangible assets as of June 30, 2017 and December 31, 2016 was $16,928 and $15,197, respectively. The change in intangibles from $10,337 as of December 31, 2016 to $9,343 as of June 30, 2017 is a result of $1,295 in amortization expense and $301 in foreign currency translation gains.

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our last annual impairment assessment as of July 31, 2016 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of June 30, 2017, we believe no indicators of impairment exist.

The change in goodwill from $18,793 as of December 31, 2016 to $19,482 as of June 30, 2017 is a result of foreign currency translation gain.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick^® In-Home HIV test to the retail trade, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Our net revenues recorded on sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of income.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

In June 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick^® HCV test in the United States. On June 30, 2016, we mutually agreed to terminate our agreement with AbbVie effective December 31, 2016. Following the termination of the agreement, AbbVie was relieved of its co-promotion obligations, including its obligation to detail the OraQuick^® HCV Rapid Test into physician offices, and has no further financial obligations to us. We are no longer obligated to compensate AbbVie for product detailing activities and are free to pursue arrangements with other pharmaceutical companies to market and promote our OraQuick^® HCV Rapid Antibody Test in the U.S. Accordingly, during the second quarter and first six months of 2017 we did not record any revenue from this co-promotion agreement. During the second quarter and first six months of 2016, $3,360 and $6,722, respectively, of exclusivity revenue was recognized and recorded as other revenue in our consolidated statements of income.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick^® Ebola Rapid Antigen test. The three-year, multi-phased grant includes an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015, BARDA exercised an option to provide $7,200 in additional funding for our OraQuick^® Ebola Rapid Antigen test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the second quarter and first six months of 2017, $454 and $874, respectively, was recognized in connection with this grant. During the second quarter and first six months of 2016, $417 and $899 respectively, was recognized in connection with this grant.

In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. In May 2017, BARDA exercised an option to provide $2,600 in additional funding for our rapid Zika test. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During the second quarter and first six months of 2017, $590 and $1,234, respectively, was recognized in connection with this grant.

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of June 30, 2017 and December 31, 2016, the reserve for sales returns and allowances was $183 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2017 and December 31, 2016 was comprised of customer prepayments of $1,477 and $1,388, respectively.

Customer and Vendor Concentrations. One of our customers accounted for 17% and 15% of our accounts receivable as of June 30, 2017 and December 31, 2016, respectively. Another customer accounted for 16% of our accounts receivable as of June 30, 2017. One of our customers accounted for approximately 20% and 15% of our net consolidated revenues for the three and six months ended June 30, 2017, respectively. Another customer accounted for 10% of our net consolidated revenues for the three months ended June 30, 2017. For the three and six months ended June 30, 2016, one of our customers accounted for approximately 11% of our net consolidated revenues, respectively.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net income	$	5,428	$	3,836	$	17,869	$	6,282

Weighted average shares of common stock outstanding:
Basic		58,478		55,543		57,708		55,497
Dilutive effect of stock options, restricted stock, and performance units		2,250		665		2,047		647

Diluted		60,728		56,208		59,755		56,144

Earnings per share:
Basic	$	0.09	$	0.07	$	0.31	$	0.11

Diluted	$	0.09	$	0.07	$	0.30	$	0.11

For the three-month periods ended June 30, 2017 and 2016, outstanding common stock options, unvested restricted stock, and unvested performance units representing 40 and 2,459 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the six months ended June 30, 2017 and 2016, outstanding common stock options, unvested restricted stock and unvested performance units representing 353 and 3,191 shares, respectively, were similarly excluded from the computation of diluted earnings per share.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange losses resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $418 and $302 for the three months ended June 30, 2017 and 2016, respectively. Net foreign exchange losses were $618 and $648 for the six months ended June 30, 2017 and 2016, respectively.

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive income (loss) separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $2,312 and $3,230 currency translation adjustments recorded in the first six months of 2017 and 2016, respectively, are largely the result of the translation of our Canadian operation’s balance sheets into U.S. dollars. Other comprehensive income at June 30, 2017 also includes net unrealized losses on marketable securities of $55.

Recent Accounting Pronouncements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, at which point we plan to adopt the standard.

The FASB allows two adoption methods under ASU 2014-09. We plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of January 1, 2018, recognizing in beginning retained earnings an adjustment for the cumulative effective of the change and providing additional disclosures comparing results to previous accounting standards.

Upon initial evaluation, we believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations related to our device and lab services for drug testing. This revenue stream amounts to less than 1% of total consolidated revenues. We will continue to evaluate the impact that the adoption of ASU 2014-09 will have on our consolidated financial statements and related disclosures, but do not anticipate the adoption will have a material impact on our financial results.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires an entity that uses the first-in, first-out method for inventory measurement to report inventory cost at the lower of cost and net realizable value versus the current measurement principle of lower of cost or market. The ASU requires prospective adoption for inventory measurements for fiscal years beginning after December 15, 2016. We adopted ASU 2015-11 on January 1, 2017. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach. Early adoption is permitted. We are evaluating the effect that ASU 2016-02 may have on our consolidated financial statements and related disclosures.

In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 provides for simplification of several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted ASU 2016-09 on January 1, 2017. Since we have a full valuation allowance against our U.S. net deferred tax assets, the adoption of this standard for recognition of tax effects of deductions for employee share awards in excess of compensation costs (“windfall”) did not have a material impact on our consolidated financial statements and related disclosures. See Note 6 – Income Taxes, for additional information. Should our full valuation allowance be reversed in future periods, the adoption of this new guidance will introduce more volatility in the calculation of our effective tax rate, depending on the Company’s share price at exercise or vesting of share-based awards as compared to grant date. The other provisions of ASU 2016-09 did not have a material impact on our consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017, subject to early adoption. The majority of the guidance in ASU 2016-15 is consistent with our current cash flow classifications and we do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which requires an entity to no longer perform a hypothetical purchase price allocation to measure goodwill impairment. Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. This update will be effective for annual and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted. We adopted ASU 2017-04 in the second quarter of 2017. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

Business Segment Information

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Business Segment Information

8. Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which primarily consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet. OSUR also derives other revenues, including exclusivity payments for co-promotion rights and other licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of customers engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, microbiome, and animal genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income.

We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three and six months ended June 30, 2017 and 2016, and asset information as of June 30, 2017 and December 31, 2016:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net revenues:
OSUR	$	24,119	$	22,926	$	45,958	$	45,125
DNAG		16,057		8,433		26,764		15,323

Total	$	40,176	$	31,359	$	72,722	$	60,448

Operating income:
OSUR	$	438	$	2,919	$	218	$	4,526
DNAG		6,449		1,430		22,540		2,522

Total	$	6,887	$	4,349	$	22,758	$	7,048

Depreciation and amortization:
OSUR	$	678	$	661	$	1,334	$	1,315
DNAG		793		727		1,557		1,423

Total	$	1,471	$	1,388	$	2,891	$	2,738

Capital expenditures:
OSUR	$	553	$	661	$	1,337	$	1,123
DNAG		136		460		230		1,606

Total	$	689	$	1,121	$	1,567	$	2,729


	June 30, 2017		December 31, 2016
Total assets:
OSUR	$	178,693	$	151,719
DNAG		79,658		56,216

Total	$	258,351	$	207,935

Our products are sold principally in the United States and Europe.

The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
United States	$	28,954	$	24,021	$	49,808	$	46,191
Europe		2,436		2,957		5,561		6,836
Other regions		8,786		4,381		17,353		7,421

	$	40,176	$	31,359	$	72,722	$	60,448

The following table represents total long-lived assets by geographic area:


	June 30, 2017		December 31, 2016
United States	$	15,966	$	15,737
Canada		4,317		4,286
Other regions		8		10

	$	20,291	$	20,033

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

Use of Estimates

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Short-Term Investments

The following is a summary of our available-for-sale securities at June 30, 2017 and December 31, 2016:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2017
Guaranteed investment certificates	$	19,281	$	—	$	—		$	19,281
Corporate bonds		36,128		—		(55	)		36,073

Total available-for-sale securities	$	55,409	$	—	$	(55	)	$	55,354

December 31, 2016
Guaranteed investment certificates	$	11,160	$	—	$	—		$	11,160

Total available-for-sale securities	$	11,160	$	—	$	—		$	11,160

At June 30, 2017 maturities of our available-for-sale securities were as follows:
Less than one year	$	55,409	$	—	$	(55	)	$	55,354

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale securities are measured as Level 1 instruments as of June 30, 2017 and December 31, 2016.

Inventories

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2017		December 31, 2016
Raw materials	$	5,410	$	5,399
Work in process		1,305		1,034
Finished goods		7,833		5,366

	$	14,548	$	11,799

Property and Equipment

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Accumulated depreciation of property and equipment as of June 30, 2017 and December 31, 2016 was $37,709 and $36,067, respectively.

Intangible Assets

Goodwill

The change in goodwill from $18,793 as of December 31, 2016 to $19,482 as of June 30, 2017 is a result of foreign currency translation gain.

Revenue Recognition

Customer Sales Returns and Allowances

Customer Sales Returns and Allowances. We do not grant return rights to our customers for any product, except for our OraQuick^® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick^® In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of June 30, 2017 and December 31, 2016, the reserve for sales returns and allowances was $183 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue

Customer and Vendor Concentrations

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net income	$	5,428	$	3,836	$	17,869	$	6,282

Weighted average shares of common stock outstanding:
Basic		58,478		55,543		57,708		55,497
Dilutive effect of stock options, restricted stock, and performance units		2,250		665		2,047		647

Diluted		60,728		56,208		59,755		56,144

Earnings per share:
Basic	$	0.09	$	0.07	$	0.31	$	0.11

Diluted	$	0.09	$	0.07	$	0.30	$	0.11

Foreign Currency Translation

Accumulated Other Comprehensive Income (Loss)

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities at June 30, 2017 and December 31, 2016:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
June 30, 2017
Guaranteed investment certificates	$	19,281	$	—	$	—		$	19,281
Corporate bonds		36,128		—		(55	)		36,073

Total available-for-sale securities	$	55,409	$	—	$	(55	)	$	55,354

December 31, 2016
Guaranteed investment certificates	$	11,160	$	—	$	—		$	11,160

Total available-for-sale securities	$	11,160	$	—	$	—		$	11,160

At June 30, 2017 maturities of our available-for-sale securities were as follows:
Less than one year	$	55,409	$	—	$	(55	)	$	55,354

Schedule of Inventories

Inventories. Inventories are stated at the lower of cost and net realizable value determined on a first-in, first-out basis and are comprised of the following:


	June 30, 2017		December 31, 2016
Raw materials	$	5,410	$	5,399
Work in process		1,305		1,034
Finished goods		7,833		5,366

	$	14,548	$	11,799

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net income	$	5,428	$	3,836	$	17,869	$	6,282

Weighted average shares of common stock outstanding:
Basic		58,478		55,543		57,708		55,497
Dilutive effect of stock options, restricted stock, and performance units		2,250		665		2,047		647

Diluted		60,728		56,208		59,755		56,144

Earnings per share:
Basic	$	0.09	$	0.07	$	0.31	$	0.11

Diluted	$	0.09	$	0.07	$	0.30	$	0.11

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and six months ended June 30, 2017 and 2016, and asset information as of June 30, 2017 and December 31, 2016:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Net revenues:
OSUR	$	24,119	$	22,926	$	45,958	$	45,125
DNAG		16,057		8,433		26,764		15,323

Total	$	40,176	$	31,359	$	72,722	$	60,448

Operating income:
OSUR	$	438	$	2,919	$	218	$	4,526
DNAG		6,449		1,430		22,540		2,522

Total	$	6,887	$	4,349	$	22,758	$	7,048

Depreciation and amortization:
OSUR	$	678	$	661	$	1,334	$	1,315
DNAG		793		727		1,557		1,423

Total	$	1,471	$	1,388	$	2,891	$	2,738

Capital expenditures:
OSUR	$	553	$	661	$	1,337	$	1,123
DNAG		136		460		230		1,606

Total	$	689	$	1,121	$	1,567	$	2,729


	June 30, 2017		December 31, 2016
Total assets:
OSUR	$	178,693	$	151,719
DNAG		79,658		56,216

Total	$	258,351	$	207,935

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area

The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
United States	$	28,954	$	24,021	$	49,808	$	46,191
Europe		2,436		2,957		5,561		6,836
Other regions		8,786		4,381		17,353		7,421

	$	40,176	$	31,359	$	72,722	$	60,448

The following table represents total long-lived assets by geographic area:


	June 30, 2017		December 31, 2016
United States	$	15,966	$	15,737
Canada		4,317		4,286
Other regions		8		10

	$	20,291	$	20,033

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands			1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($)	Jun. 12, 2015 USD ($)	May 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2017 USD ($) Supplier shares	Jun. 30, 2016 USD ($) shares	Jun. 30, 2017 USD ($) Supplier shares	Jun. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 107,959,000					$ 104,872,000		$ 104,872,000		$ 107,959,000
Fair value of plan assets	1,980,000					3,220,000		3,220,000		1,980,000
Accumulated depreciation of property and equipment	36,067,000					37,709,000		37,709,000		36,067,000
Intangible Assets, Net	10,337,000					9,343,000		9,343,000		10,337,000
Intangible Assets, Accumulated Amortization								1,295,000
Intangible Assets, Foreign currency translation gains								301,000
Accumulated amortization of intangible assets	15,197,000					16,928,000		16,928,000		15,197,000
Amount of goodwill at period end	18,793,000					19,482,000		19,482,000		18,793,000
Revenue recognized						0	$ 3,360,000	0	$ 6,722,000
Maximum value of grant revenue from clinical and regulatory activities		$ 10,400,000		$ 16,600,000
Initial grant revenue from clinical and regulatory activities		1,800,000		7,000,000
Remaining grant revenue from clinical and regulatory activities		$ 8,600,000		$ 9,600,000
Period of grant		3 years		6 years
Additional contract revenue from clinical and regulatory activities			$ 2,600,000		$ 7,200,000
Contract revenues from clinical and regulatory activities						590,000		1,234,000
Reserve for sales return and allowances								183,000		217,000
Deferred revenue	1,388,000					1,477,000		1,477,000		1,388,000
Net foreign exchange losses						(418,000)	(302,000)	(618,000)	(648,000)
Accumulated foreign currency adjustments included in other comprehensive loss amounted						2,312,000	$ 3,230,000	2,312,000	$ 3,230,000
Unrealized loss on marketable securities						(55,000)		(55,000)
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	83,704,000					$ 60,987,000		$ 60,987,000		83,704,000
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares						40	2,459	353	3,191
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue	$ 1,388,000					$ 1,477,000		$ 1,477,000		$ 1,388,000
AbbVie [Member] \| Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement								Dec. 31, 2016
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk	15.00%							17.00%
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk								16.00%
Customer Two [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk						20.00%		15.00%
Customer Three [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk						10.00%
Customer Four [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							11.00%		11.00%
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities						$ 454,000	$ 417,000	$ 874,000	$ 899,000
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Certificates of deposit maturity date								Feb. 28, 2018
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets								15 years
Maximum [Member] \| Net Consolidated Revenue [Member] \| Revenue from Rights Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk								1.00%
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								10 years
Maximum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit								0.84%
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets								7 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets								2 years
Minimum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit								0.68%
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier						2		2

Stockholders' Equity - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 21,014,000	$ 209,000
Income tax benefit realized from stock option exercises during period	0	0
Total compensation cost	$ 3,631,000	$ 2,942,000
Amount share repurchase program of common shares			$ 25,000,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	423
Average price of common stock		$ 6.29
Total cost of common stock purchased and retired		$ 2,660,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 21,014,000	209,000
Total compensation cost	1,007,000	1,387,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,355,000	$ 1,401,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	120,000	117,000
Restricted shares of common stock and stock options, aggregate values	$ 1,209,000	$ 651,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,269,000	$ 154,000

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 637	$ 484
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	59,330,000	56,001,000
Common stock, shares outstanding	59,330,000	56,001,000

The Company	6 Months Ended
The Company	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, a rapid point-of-care HIV in-home test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market and a rapid point-of-care HIV self-test used in certain international markets. We also manufacture and sell devices used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomic, personalized medicine, microbiome and animal genetic markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies and mass merchandisers, and to consumers over the internet.

Credit Facility	6 Months Ended
Credit Facility	Jun. 30, 2017
Debt Disclosure [Abstract]
Credit Facility	4. Credit Facility On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit subfacility of $2,500), with an option to request, prior to the second anniversary of the closing date, that the lender, at its election, provide up to $5,000 of additional revolving commitments. Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings outstanding under the Credit Agreement at June 30, 2017 and December 31, 2016. Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019. In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of June 30, 2017 and December 31, 2016, we were in compliance with all applicable covenants in the Credit Agreement.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Stock-Based Awards We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options or to issue restricted stock, or redeem performance-based restricted stock units, we issue new shares rather than purchase shares on the open market. Total compensation cost related to stock options for the six months ended June 30, 2017 and 2016 was $1,007 and $1,387, respectively. Net cash proceeds from the exercise of stock options were $21,014 and $209 for the six months ended June 30, 2017 and 2016, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was recognized in the consolidated statements of income from stock option exercises during these periods. Compensation cost of $1,355 and $1,401 related to restricted shares was recognized during the six months ended June 30, 2017 and 2016, respectively. In connection with the vesting of restricted shares and options during the six months ended June 30, 2017 and 2016, we purchased and immediately retired 120 and 117 shares with aggregate values of $1,209 and $651, respectively, in satisfaction of minimum tax withholding obligations. Commencing in 2016, we granted to certain executives performance-based restricted stock units (“PSUs”). Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate. Compensation cost of $1,269 and $154 related to PSUs was recognized during the six months ended June 30, 2017 and 2016, respectively. Stock Repurchase Program On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the six months ended June 30, 2017. During the six months ended June 30, 2016, we purchased and retired 423 shares of common stock at an average price of $6.29 per share for a total cost of $2,660 under this share purchase agreement.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes During the three and six months ended June 30, 2017, we recorded tax expense of $1,555 and $5,452, respectively. During the three and six months ended June 30, 2016, we recorded tax expense of $173 and $234, respectively. Tax expense reflects taxes due to state and Canadian taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of June 30, 2017 relate to the tax effects of the basis difference between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes. Tax expense in the first six months of 2017 reflects the additional Canadian taxes due as a result of the $12,500 gain from the settlement of our patent infringement and breach of contract litigation against Ancestry.com DNA LLC and its contract manufacturer. In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate as of both June 30, 2017 and December 31, 2016 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three and six-month periods ended June 30, 2017 and 2016. The new accounting guidance under ASU 2016-09 allows for the recognition of excess tax benefits regardless of whether the deduction reduces taxes payable. On January 1, 2017, we recorded a cumulative-effect adjustment to retained earnings of $3,391 to recognize the increase in our net operating loss carryforwards from the cumulative excess tax benefits not recognized in periods prior to January 1, 2017. A corresponding $3,391 increase to our valuation allowance associated with this tax benefit was also recorded to retained earnings thereby resulting in a net impact to retained earnings of $0.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Standby Letters of Credit In 2016, we established four standby letters of credit in the aggregate amount of $1,831, naming international customers as the beneficiaries. These letters of credit were required as a performance guarantee of our obligations under our product supply contracts with those customers and are collateralized by certificates of deposit maintained at a commercial bank. Litigation From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 55,409	$ 11,160
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(55)
Fair Value	55,354	11,160
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	19,281	11,160
Gross Unrealized Gains	0	0
Fair Value	19,281	$ 11,160
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	36,128
Gross Unrealized Gains	0
Gross Unrealized Losses	(55)
Fair Value	36,073
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	55,409
Gross Unrealized Gains	0
Gross Unrealized Losses	(55)
Fair Value	$ 55,354

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Raw materials	$ 5,410	$ 5,399
Work in process	1,305	1,034
Finished goods	7,833	5,366
Inventories	$ 14,548	$ 11,799

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 6,877	$ 7,685
Income taxes payable (receivable)	1,463	(39)
Professional fees	804	982
Royalties	761	715
Other	2,187	1,971
Accrued Expenses, Total	$ 12,092	$ 11,314

Credit Facility - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000

Income Taxes - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Taxes [Line Items]
INCOME TAX EXPENSE		$ 1,555,000	$ 173,000	$ 5,452,000	$ 234,000
Gain from settlement of litigation against Ancestry.com DNA LLC				$ 12,500,000
U.S. federal or state deferred income tax expense or benefits		$ 0			$ 0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000
Net impact of cumulative-effect adjustment to retained earnings	0
Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] \| Valuation Allowance, Operating Loss Carryforwards [Member]
Income Taxes [Line Items]
Cumulative-effect adjustment to retained earnings	$ 3,391,000

Commitments and Contingencies - Additional Information (Detail) - Standby Letters of Credit [Member] $ in Thousands	Dec. 31, 2016 USD ($) Debt_Instruments
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit \| $	$ 1,831
Debt instrument, number of letters of credit \| Debt_Instruments	4

Business Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2